氯氮平片辅助治疗PD合并精神障碍患者的有效性及不良反应研究

目的:对氯氮平片在帕金森病(Parkinson’s disease,PD)合并精神障碍辅助治疗中的应用价值予以探讨。方法:选取50例我院2013年1月1日—2019年6月30日接诊的PD合并精神障碍患者进行研究,按照随机数表法分为对照组和观察组。对照组用多巴丝肼,观察组联合氯氮平片,对比治疗效果。结果:观察组疾病治疗总有效率96.00%(24/25)高于对照组68.00%(17/25),差异有统计学意义(P<0.05),不良反应发生率8.00%(2/25)与对照组20.00%(5/25)差异无统计学意义(P>0.05);观察组UPDRD评分、VGI-S评分和BPRS评分明显低于对照组,差异有统计学意义(P<0.05)。结论:氯氮平片辅助治疗PD合并精神障碍患者,既可提高临床疗效,也不会增加用药后不良反应,安全性高,值得推广。

Efficacy and side effects of clozapine tablets in the treatment of PD patients with mental disorders

Objective:To explore the value of clozapine tablets in the adjuvant treatment of Parkinson's disease(Parkinson's disease,PD)complicated with mental disorders.Methods:50 patients with PD combined with mental disorders treated in our hospital from January 1,2013 to June 30,2019.20 were selected for study,and were divided into the control group and the observation group according to the random digital table method.The control group was treated with dopamine and the observation group was treated with clozapine.Results:The total effective rate of disease treatment in the observation group was 96.00%(24/25),which was higher than that in the control group(68.00%).The incidence of adverse reactions was 8.00%(2/25),and there was no significant difference between the two groups(P>0.05),but the UPDRD score,VGI-S score and BPRS score in the observation group were significantly lower than those in the control group(P<0.05).Conclusion:Clozapine in the treatment of PD patients with mental disorders can not only improve the clinical efficacy,but also do not increase the adverse reactions after treatment,and the safety is high,which is worth popularizing.